Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

SI Units: 2019 Redefinition01:13

SI Units: 2019 Redefinition

3.4K
Measurement is an indispensable part of analytical chemistry. The result of measurement helps quantify a substance's physical property and compare it with the physical property of another substance. Each measurement comprises two components - a number indicating the magnitude and a unit of measurement as a standard for comparison. Further, the same quantity can be measured using different units of measurement, which leads to differences in magnitude.
A standard set of units has been defined...
3.4K
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

425
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
425
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

155
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
155
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

250
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
250
Factors Influencing Drug Absorption: Drug Dissolution01:27

Factors Influencing Drug Absorption: Drug Dissolution

1.1K
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
1.1K
Factors Affecting Protein-Drug Binding: Drug-Related Factors01:18

Factors Affecting Protein-Drug Binding: Drug-Related Factors

464
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
464

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Student Pharmacist State Anxiety on Vasopressor Calculation Accuracy in Advanced Cardiac Life Support Simulations.

American journal of pharmaceutical education·2024
Same author

A Tribute to Dr. Daniel A. Hussar.

The Senior care pharmacist·2021
Same author

New Drugs 2021, Part 2.

Nursing·2021
Same author

New Drugs 2021, Part 1.

Nursing·2021
Same author

New Drug Update 2020.

The Senior care pharmacist·2021
Same author

New drugs 2020, part 3.

Nursing·2020
Same journal

Can Technology Simplify Aging Care-or Just Shift the Complexity?

The Senior care pharmacist·2026
Same journal

Transitioning Medication-Related Home Visits to a Cognitively Accessible Digital Intervention in Home Care: A Practice Innovation Pilot.

The Senior care pharmacist·2026
Same journal

Perception of Technology to Support Medication Management Among Community-dwelling African American Older Adults.

The Senior care pharmacist·2026
Same journal

ASCP Policy Review Committee.

The Senior care pharmacist·2026
Same journal

Initial Evaluation of L-mMRC Severity Tool in Staging COPD in the Skilled Nursing Setting.

The Senior care pharmacist·2026
Same journal

Dispense This: How AI Is Reshaping Pharmacy's Clinical Services.

The Senior care pharmacist·2026
See all related articles

Related Experiment Video

Updated: Jan 27, 2026

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
06:05

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time

Published on: February 19, 2021

1.6K

2019 New Drug Update.

Daniel A Hussar, Laura A Finn

    The Senior Care Pharmacist
    |April 3, 2019
    PubMed
    Summary
    This summary is machine-generated.

    This review assesses five new drugs from 2018 for common elderly conditions, including diabetes, hyperkalemia, influenza, and glaucoma. Each drug is rated based on its properties, advantages, and disadvantages.

    More Related Videos

    Updated Protocol for the Assembly and Use of the Minibioreactor Array (MBRA)
    09:38

    Updated Protocol for the Assembly and Use of the Minibioreactor Array (MBRA)

    Published on: September 5, 2025

    863
    Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
    08:22

    Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

    Published on: October 7, 2017

    8.5K

    Related Experiment Videos

    Last Updated: Jan 27, 2026

    The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
    06:05

    The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time

    Published on: February 19, 2021

    1.6K
    Updated Protocol for the Assembly and Use of the Minibioreactor Array (MBRA)
    09:38

    Updated Protocol for the Assembly and Use of the Minibioreactor Array (MBRA)

    Published on: September 5, 2025

    863
    Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
    08:22

    Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

    Published on: October 7, 2017

    8.5K

    Area of Science:

    • Geriatric Medicine
    • Pharmacology
    • Drug Development

    Background:

    • Elderly individuals often experience multiple chronic conditions.
    • New pharmaceutical agents are continually developed to address unmet medical needs in this population.
    • Evaluating new drugs for efficacy and safety in the elderly is crucial.

    Purpose of the Study:

    • To review five new drugs marketed in 2018 for conditions prevalent in the elderly.
    • To discuss the uses and key properties of these new pharmaceutical agents.
    • To rate each new drug using a standardized comparison system.

    Main Methods:

    • Selection of five new drugs launched in 2018 targeting common geriatric conditions.
    • Analysis of drug uses, properties, advantages, and disadvantages.
    • Application of the New Drug Comparison Rating (DAH) system for evaluation.

    Main Results:

    • Detailed discussion of two agents for type 2 diabetes mellitus.
    • Review of a new drug for hyperkalemia.
    • Assessment of an antiviral agent for influenza.
    • Evaluation of a new treatment for open-angle glaucoma and ocular hypertension.

    Conclusions:

    • The review provides a comparative analysis of new drugs relevant to elderly care.
    • The DAH rating system offers a structured approach to evaluating new pharmaceutical interventions.
    • Informed decision-making for geriatric pharmacotherapy is supported by this assessment.